Leung, Brenda M. Y. http://orcid.org/0000-0002-4699-8086
Srikanth, Priya http://orcid.org/0000-0002-0906-6757
Robinette, Lisa http://orcid.org/0000-0002-9314-9538
Bruton, Alisha M. http://orcid.org/0000-0002-5929-3149
Tost, Gabriella http://orcid.org/0000-0003-1464-4918
Hatsu, Irene http://orcid.org/0000-0003-0501-9088
Arnold, L. Eugene http://orcid.org/0000-0002-0886-0692
Johnstone, Jeanette M. http://orcid.org/0000-0003-3947-5540
Funding for this research was provided by:
Calgary Foundation (Nutrition and Mental Health Fund)
Emmy Droog Chair in Complementary and Alternative Healthcare
National Center for Complementary and Integrative Health (T32 #AT002688, R90AT008924; T32 AT002688; K23 AT012068-01)
National Center for Advancing Translational Sciences (UL1TR002369; UL1TR002733, UL1TR002369; UL1TR002733, UL1TR000128)
Foundation for Excellence in Mental Health Care (Nutrition and Mental Health Research Fund)
Gratis Foundation
Article History
Received: 11 November 2022
Accepted: 16 May 2023
First Online: 8 June 2023
Declarations
:
: Dr. Arnold has received research funding from Forest, Lilly, Noven, Shire, Supernus, Roche, and YoungLiving (as well as NIH and Autism Speaks); has consulted with Pfizer, Tris Pharma, and Waypoint; and been on advisory boards for Arbor, Ironshore, Otsuka, Pfizer, Roche, Seaside Therapeutics, Shire. The other authors declare that they have no competing interests.
: The MADDY study was approved by the US Food & Drug Administration under investigational new drug (IND) #127832, Health Canada (Control #207742), the University of Calgary Conjoint Health Research Ethics Board (CHREB) REB #17-0325, Institutional Review Boards at OHSU IRB #16870, and OSU IRB # 2017H0188.
: All participants provided written parental consent and child assent prior to participation.
: All authors consent to the publication of this manuscript.
: Not applicable.
: Not applicable.